The FRL1 Antibody is a polyclonal rabbit antibody targeting FMNL1 (Formin-like 1), a cytoplasmic formin protein critical for actin cytoskeleton dynamics, cell adhesion, and migration. FMNL1 is highly expressed in immune cells, including macrophages, where it regulates podosome formation—actin-rich adhesion structures involved in tissue invasion and immune surveillance.
Key Properties
Property
Value
Source
Antigen
FMNL1 (Formin-like 1)
Clonality
Polyclonal
Host
Rabbit
Reactivity
Human, Mouse, Rat
Immunogen
16-aa peptide near C-terminus (last 50 aa)
Purification
Affinity chromatography via peptide column
Storage Buffer
PBS with 0.02% sodium azide
Observed MW
68 kDa (Boster Bio), 121 kDa (VWR)
Applications
ELISA, Western Blot (WB), Immunofluorescence (IF)
Key Studies
Podosome Dynamics
FMNL1 Localization: Endogenous FRL1 co-localizes with β3 integrin in podosome cores, essential for actin bundling and stabilization.
siRNA Knockdown: Loss of FMNL1 reduces podosome number by 33–65% and increases average podosome size, indicating disrupted actin organization.
Adhesion Defects: FMNL1 depletion correlates with reduced macrophage adhesion (up to 45% decrease).
Actin Regulation
Bundling Activity: FMNL1 may bundle actin filaments, counteracting severing processes to maintain podosome integrity.
Isoform-Specific Expression: Macrophages express FMNL1α and FMNL1γ isoforms, but not FMNL1β.
Optimized Protocols
Application
Dilution
Validation
Notes
Western Blot
1–2 μg/mL
Mouse EL4 lysate
Detects 68 kDa band in Boster Bio
Immunofluorescence
20 μg/mL
Mouse EL4 cells
Visualizes cytoplasmic FMNL1
ELISA
Not specified
General reactivity confirmed
Cross-reactivity with human/mouse/rat
Critical Considerations
Molecular Weight Discrepancy
Observed MW varies between 68 kDa (Boster) and 121 kDa (VWR), likely due to isoform differences or post-translational modifications.
Species Specificity
Validated for human, mouse, and rat samples; no data on other species.
Storage Stability
Stable at 4°C for 3 months or –20°C for 1 year; avoid freeze-thaw cycles.